2:15 Labiotech.eu news
5:12 Phase Genomics
16:44 IRB Barcelona
29:37 Ilya Pharma
43:00 Krystal Biotech
53:54   JLL

Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO of Phase Genomics.

We also have a new weekly addition, as JLL will be joining us with a look at financial news. This week, we’re joined by Robert Coughlin, JLL managing director and New England Life Science Practice Group lead.

CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types of cancer and HIV.

Scientists at IRB Barcelona, led by ICREA researcher Fran Supek, have now reported that, depending on the targeted spot of the human genome, CRISPR gene editing can give rise to cell toxicity and genomic instability. 

Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds 

Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.

These are: one in India, and continuation patents in China, Australia and the U.S. This means the company’s method for using modified bacteria for treatment of both mucosal and cutaneous wounds in humans and animals has patent protection in all major markets.

Ilya is currently developing a portfolio of three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.

Krystal Biotech gets green light for cystic fibrosis trial

U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application.

The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to the respiratory cells in the lungs. 

By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has the potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation.

Phase Genomics using ProxiMeta for phage-bacteria interactions

Phase Genomics, Inc., a developer of proximity ligation-based genomic solutions, recently received $5.5M in combined non-dilutive funding from the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. With the new funding, Phase Genomics will leverage its phage-bacteria interactome repository to power the development of an  AI-driven predictive engine for therapeutic phage discovery.

The new financing will allow the company to harness its proximity-guided metagenomics platform, ProxiMeta, to develop the world’s largest atlas of phage-bacteria interactions and use machine learning tools to identify phages that can be used in therapeutic settings such as C. difficile infections, ulcerative colitis, and Crohn’s disease. 
<